ISO 27001 Certified
SOC 2 Type II
HIPAA & GDPR Ready
For a complete list of security and privacy certifications visit the Illumina Trust Center.
3500+
organizations
10,000+
users
5+ million
genomes across active programs
Deploy award‑winning bioinformatics solutions, benchmarked by precisionFDA and powered by proprietary genomic AI published in leading peer‑reviewed journals. Illumina algorithm design accurately accelerates your discoveries with and provides greater confidence in your results.
Access genetic disease, oncology, multiomics, and population health research workflows in one place. A shared data layer keeps everything connected, helping you build a growing knowledge base so you can be ready for what’s next.
Take advantage of automatic sequencer-to-platform data streams, input-free pipeline runs, and interpretation-ready results with no file transfers. Software scales without slowdowns or setbacks. Fewer handoffs mean fewer errors, and your team stays focused on science, not operations.
One unified platform for every team, every genomic and multiomic application, at any scale.
BaseSpace
Sequencer-to-cloud connectivity with zero-touch data ingest and instant pipeline launch
BaseSpace connects every Illumina sequencer to BioInsight Platform. Data streams automatically in real time, triggering downstream DRAGEN analysis without manual uploads, file transfers, or scripts.
DRAGEN
One bioinformatic engine for every variant type, designed for speed with proven accuracy
DRAGEN unifies germline, somatic, and transcription analysis (SNVs, indels, CNVs, SVs, repeat expansions, fusions) in a single pipeline, replacing the patchwork of tools most labs maintain today. Purpose-built Field Programmable Gate Array (FPGA) acceleration delivers a 30× whole-genome analysis in under 25 minutes, with accuracy proven by four PrecisionFDA challenge wins. The same engine extends to methylation and spatial analysis, giving your operation one secondary analysis foundation with results ready for downstream interpretation without manual handoffs.
Emedgene and Connected Insights
AI-assisted interpretation that resolves more variants with confidence, across germline and somatic research cases, in minutes instead of hours
Emedgene prioritizes causative germline variants with 97% accuracy.1 Connected Insights classifies somatic oncogenicity with 96% concordance with ClinGen expert standards. Unified by DRAGEN variant calling and peer-reviewed AI for classification and prioritization, this platform grows with your test menu across germline and somatic applications. Each resolved case compounds institutional knowledge and builds a durable evidence base that enables faster resolution and higher confidence in future cases.
Illumina Connected Multiomics
See a more complete biological picture
Illumina Connected Multiomics provides a shared environment for collaborators to statistically analyze, visualize, and biologically interpret multiomic data, including genomics, transcriptomics, epigenomics, and proteomics, across bulk, single cell, and spatial modalities. Researchers work from a common workspace with industry-standard statistical methods, evidence-based AI, and curated biological knowledge bases. Each study builds on the last, enabling cumulative, reusable insights that connect research results to known biological pathways and mechanisms.
Illumina BioInsight Data
Combine your results with curated genomic cohorts and multiomic data sets linked to real-world outcomes
Single-site studies lack the statistical power and population diversity to validate discoveries at scale. The platform is purpose-built for population-scale research, target discovery, AI model training, and research-stage development.
The Billion Cell Atlas maps how genetic changes play out across billions of cells for AI-driven target identification. The Alliance for Genomic Discovery delivers more than 312,000 whole genomes across one of the largest genomic research data sets of its kind. Custom co-created cohorts link multiomic data to real-world outcomes for biomarker validation, risk stratification, and indication expansion.
Explore how drug targets backed by genetic evidence have 2.6× higher approval rates. Population programs gain reference panels that no single institution could build alone. Illumina data assets help you get there faster.
BioInsight Platform Core gives technical teams a more secure and smarter foundation for building custom pipelines, visualizations, dashboards, and applications. With storage, algorithms, toolkits, compute, enterprise-grade security, and auditing already in place, you can spend less time managing infrastructure and more time focusing on differentiation.
Bring Nextflow, CWL, or fully custom Docker containers into BioInsight Platform Core. Stream data directly from Illumina sequencers, run DRAGEN or custom pipelines, and chain pipelines together without moving files. Import pipelines directly from GitHub. Stream data directly from BaseSpace, so teams do not need to wait for a manual step.
Access DRAGEN at two levels. Pre-built pipelines cover germline, somatic, RNA, methylation, joint genotyping, single-cell, spatial, and proteomics workflows. The toolkit layer exposes the building blocks underneath, including the multigenome mapper with pangenome reference, standalone variant callers, targeted callers, repeat expansion detection, and ORA compression. All capabilities are available through the CLI or API, so you can deploy award-winning accuracy in the way that fits your workflows.
Launch JupyterLab workspaces with direct access to project data and pipelines. Build custom analyses and visualizations in notebooks, then share them across your team through custom Bench images. Aggregate sample outcomes in Base for cohort-level queries, GWAS and PheWAS, and QC trend analysis. Teams can bring their own custom notebook environments or start from sample outcomes for cohort-level queries.
BioInsight Platform Core includes role-based access controls, team workspaces, and project-level permissions out of the box. Zero-copy data sharing across teams helps reduce duplication, while support for your own S3 bucket allows storage to scale without limits. The platform is ISO 27001 certified, SOC 2 Type II attested, encrypted at rest and in transit, and supported by full audit trails for every operation. Teams can start with a production-ready platform from the first login.
AI-assisted algorithms support every layer of analysis, from variant calling through interpretation and discovery. Built on peer-reviewed science, these capabilities help surface patterns and findings that traditional approaches can overlook.1–7
Machine-learning driven variant calling and recalibration help reduce false positives and recover variants in difficult-to-map regions. Somatic artifact suppression separates real mutations from noise, while PrimateAI-3D predicts pathogenicity for missense variants with no prior literature. SpliceAI identifies splice-altering variants in noncoding regions that other tools may miss. Together, these capabilities improve calling improve calling and prediction accuracy across analysis workflows.
Illumina BioInsight Platform provides traceable recommendations with evidence, so you can confidently review results.
For germline research, Explainable AI incorporates PrimateAI-3D, SpliceAI, and PromoterAI to prioritize variants, automate ACMG classification, and match phenotypes to gene candidates. PromoterAI identifies regulatory variants that may be responsible for up to 6% of rare disease genetic causes. Combined, these three algorithms substantially expand the range of identifiable causative variants.
For somatic research, AI-assisted oncogenicity classification applies PrimateAI-3D, SpliceAI, and more than 55 knowledge sources to classify somatic variants.
AI analysis suggestions guide multiomic exploration by surfacing patterns across transcriptomic, proteomic, and epigenomic data sets. Teams can correlate across data types, explore spatial relationships across tissue samples, and visualize patterns that single-omic approaches may miss. Guided exploration turns multimodal data into testable hypotheses.
Genetic disease research
Go from sequencing to AI-assisted variant prioritization and reporting. BioInsight Platform supports genomes, exomes, panels, and microarrays for rare disease, hereditary conditions, newborn screening, and carrier screening with explainable AI.
Precision oncology research
Move from tumor sequencing to automated oncogenicity classification, therapy matching, and structured research reporting. BioInsight Platform supports targeted panels, comprehensive genomic profiling (CGP), liquid biopsy, heme, and whole-genome sequencing (WGS) with proprietary AI algorithms and over 55 curated knowledge sources.
Multiomics discovery
From individual omics to integrated multimodal analysis, BioInsight Platform brings transcriptomics, proteomics, epigenomics, and genomics together with single-cell and spatial analysis in one visual environment.
Population genomics
From cohort sequencing to joint calling, variant discovery, and population-scale analysis, BioInsight Platform orchestrates national programs and biobanks with elastic compute, iterative genotyping, and full data residency.
Drug discovery
Access curated genomic and multiomic data sets for target discovery, AI model training, and research-stage development. The Alliance for Genomic Discovery provides more than 312,000 whole genomes for population-scale analysis. The Billion Cell Atlas maps genetic changes across billions of cells for single-cell drug target identification. Custom cohorts co-created with Illumina link multiomic data to real-world outcomes.
Watch how researchers and labs are using BioInsight Platform software to accelerate discovery and scale operations in these on-demand webinars.
Variant discovery with DRAGEN v4.5
Watch how machine learning-driven variant calling delivers improved accuracy across germline, somatic, and multiomic workflows.
AI-assisted strategies for rare disease research
Learn how NHS North West Genomic Laboratory Hub shares its real-world implementation of AI-assisted strategies for scalable rare disease analysis.
See how the MEASURE-ATLAS research study used whole genome sequencing and integrated informatics to uncover missed pathogenic events in 10% of AML research cases across 18 U.S. cancer centers.
Actionable research insights with Illumina Connected Multiomics
Learn more about a proteomics case study exploring links between cancer and cardiovascular health.
Try the complete BioInsight Platform free for 30 days with no credit card, no purchase order, and no obligations. When you're ready to scale, pay only for what you use or choose the option to save with volume discounts.
Most popular
FREE for 30 days
Perfect for: Evaluation and pilot projects
Full platform access for 30 days
No credit card required
No upfront commitment
100 Illumina BioInsight Credits included
Scale with flexibility
Perfect for: Variable workloads and usage
No upfront commitment
Pay only for what you use
Monthly billing
Premium support options available
Cancel anytime
Unlock volume-based savings
Perfect for: Production and predictable usage
Choose 1-, 3-, or 5-year plans
Premium support options available
Upfront or monthly billing options
Get answers to common questions about BioInsight Platform.
Still have questions? We are here to help.
Signing up to start a free trial enables you to get full access to BioInsight Platform in minutes. You can connect a sequencer or directly upload FASTQ or VCF files, launch a DRAGEN pipeline, and see results the same day. Explore sample data sets across the platform to evaluate capabilities before committing. Products like Emedgene and Illumina Connected Insights include guided onboarding to configure workflows for your specific research needs.
Most teams start with a single workflow: DRAGEN for secondary analysis, Emedgene for rare disease interpretation, or Connected Insights for oncology research. Illumina onboarding guides your team through configuration, and a single-product setup can be operational in hours. From there, add workflows as your needs grow with no re-implementation required.
BioInsight Platform pricing is usage-based, measured in Illumina BioInsight Credits (BIC) where 1 BIC = $1 USD. Start with a free 30-day trial with 100 BIC included and no credit card or purchase order required. From there, you can purchase credits to pre-fund your account, or you can select monthly billing with no commitment. You can also connect with our Illumina informatics sales team and lock in volume discounts with 1-, 3-, or 5-year commitments. There are no fees for platform access.
The free trial includes full access to every BioInsight Platform product for 30 days, 100 BioInsight Credits, and 1 TB of storage. No credit card or purchase order required. Your data and pipeline configurations persist whenif you continue after the trial.
With BioInsight Platform, you don’t need to provision servers, manage storage, fully configure security, build pipeline orchestration, or maintain software updates. Building your own platform typically requires investing months of engineering effort and multiple full-time engineers before running your first production workflow. BioInsight Platform is production-ready from the first time you log in, with usage-based pricing that includes infrastructure, maintenance, and updates.
The platform works alongside existing infrastructure. Connect Illumina sequencers for automatic data ingest, import existing pipelines from GitHub, bring your own S3 storage, and integrate with LIMS or IT systems via API.
More than 3,500 organizations and 10,000 users run on BioInsight Platform today. This growing community across life sciences and genomics continues to shape the platform across basic science, clinical research, and at-scale bioinformatics operations.
Instantly. BioInsight Platform provides elastic compute that scales up and down with demand. There is no capacity planning, no provisioning delay, and no infrastructure ceiling. Teams have gone from pilot projects to processing hundreds of thousands of genomes without re-architecture.
Yes. Many large-scale studies and national programs use BioInsight Platform, such as Singapore PRECISE (100,000+ genomes) and the Alliance for Genomic Discovery (312,000 genomes) to run production-scale workloads. Clinical research labs, sequencing service providers, and biopharma companies rely on BioInsight Platform with pricing that that scales with demand. Whether you are just getting started or ready to tackle large projects, pricing grows with you, ensuring your costs stay aligned with your scale.
BioInsight Platform and its associated products are under continuous development. Some products release updates monthly, others quarterly or semi-annually. Visit help.connected.illumina.com for the latest software updates and release notes. Contact your Illumina representative or schedule a demo to discuss the roadmap for your specific use case.
BioInsight Platform is ISO 27001 certified, SOC 2 Type II attested, and supports HIPAA and GDPR compliance. Encryption at rest and in transit, role-based access controls, multi-factor authentication, and full audit trails are built in. Visit the Illumina Trust Center for detailed documentation that your security team can review directly.
From sample management to AI-assisted interpretation, discover how BioInsight Platform removes friction at every step.
Pricing transparency
Illumina BioInsight Credits (BIC) are our universal software currency. 1 BIC = $1 USD. As products transition to BIC billing, all pricing will be published in BIC at US list rates.
Purchasing in your local currency
BIC are available in local currencies through your Illumina representative or authorized channel partner.
References